Treatment | Children with Cancer UK

Filter by Cancer Type

Immunotherapy for infant and childhood MLL-rearranged acute lymphoblastic leukaemia

Improving immunotherapies for the treatment of leukaemia

Dr Anindita Roy and Professor Anastasios Karadimitris, University of Oxford and Imperial College London

Relapse-specific therapeutic vulnerability evaluation in childhood and young adult ALL (REVEALL)

Improving outcomes for children whose leukaemia relapses after treatment

Dr David O’Connor, Professor Marc Mansour and Dr Jack Bartram, University College London Cancer Institute and Great Ormond Street Institute of Child Health

Getting ahead of drug resistance in diffuse midline glioma (including diffuse intrinsic pontine glioma)

Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma

Prof. Chris Jones, Institute of Cancer Research

Designing drugs to cut acute lymphoblastic leukaemia (ALL) at its roots

Designing drugs to cut acute lymphoblastic leukaemia (ALL) at its roots

Prof. Olaf Heidenreich, Newcastle University and the Princess Maxima Centre for Paediatric Oncology

Unravelling the world-wide survival disparities in children, teenagers and young adults with leukaemia and lymphoma

Global surveillance of survival from haematological malignancies in children, teenagers and young adults

Dr Claudia Allemani, London School of Hygiene and Tropical Medicine

Engineering the immune system to treat T-cell acute lymphoblastic leukaemia (T-ALL)

Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL)

Dr Marc Mansour, UCL Cancer Institute

1 2 3 … 17